Unchanged triclabendazole kinetics after co-administration with ivermectin and methimazole: failure of its therapeutic activity against triclabendazole-resistant liver flukes

BACKGROUND: The reduced drug accumulation based on enhanced drug efflux and metabolic capacity, identified in triclabendazole (TCBZ)-resistant Fasciola hepatica may contribute to the development of resistance to TCBZ. The aim of this work was to evaluate the pharmacokinetics and clinical efficacy of...

Descripción completa

Detalles Bibliográficos
Autores principales: Ceballos, Laura, Moreno, Laura, Alvarez, Luis, Shaw, Laura, Fairweather, Ian, Lanusse, Carlos
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Research article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2829539/
https://www.ncbi.nlm.nih.gov/pubmed/20128898
http://dx.doi.org/10.1186/1746-6148-6-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2829539/
https://www.ncbi.nlm.nih.gov/pubmed/20128898
http://dx.doi.org/10.1186/1746-6148-6-8

Ejemplares similares